The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
about
CIViC databaseTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceClinical applications of liquid biopsies in gastrointestinal oncologyOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerNew frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targetsPharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery.Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive.Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.Genomic landscape of cell-free DNA in patients with colorectal cancer.Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells.Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance.Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors
P2860
Q27612411-310F1F23-35CA-45AA-BC97-C3032CA332F7Q28071772-238F762D-C3B8-4B24-9550-96008FEB4E1BQ28073730-C20A4C5B-762B-4C2D-9504-BAE574B42B9BQ28077545-3E48B87B-387E-4FC8-9BB8-C8D0AE8AC837Q33731804-94364BB4-17E1-48B5-BD05-1A283AF72410Q38679229-D3C10E3A-997B-4733-8418-45A08A33D282Q38729111-B37902D3-00B3-4165-8916-0572B890E9D6Q38794338-EABBAB28-E84A-41E2-9FFF-9257BA1A6DB7Q38989275-975DD396-5137-457C-AE1C-E8F71453AFF7Q39223563-637F7073-8653-402C-BA99-3C0CFB5436EDQ39255218-D8F57B7B-07B3-4B67-8A1C-11AA89A3E11AQ42139529-86ED0251-5071-4662-A3EA-ADAEE470DE68Q42200131-96322DA1-BE5B-4D85-A495-EC7F566DDC95Q42360041-88F1D280-B200-414F-9C9C-1AA7505A25B9Q45989066-96CB4963-19B1-4733-A119-4B5DF9157C01Q46334692-1A3801B7-4031-4A65-8F53-37D39CD3441EQ46744252-C9E10A2F-D139-4F68-A4E1-A06077FC73EDQ47439465-859C790E-11FB-44B9-9988-8B3A24144BEDQ48501675-0490208C-949A-43B1-8CAD-7E47A5857212Q55342871-14E44E4E-2617-4A32-88EE-BF6E3F20DA47Q55363919-DB3E5115-0AA6-4EB3-AAD3-BB21156C4163Q57652734-218466E9-775C-4400-B920-AEBFD6699CD9
P2860
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The First-in-class Anti-EGFR A ...... utations in Colorectal Cancer.
@ast
The First-in-class Anti-EGFR A ...... utations in Colorectal Cancer.
@en
The First-in-class Anti-EGFR A ...... utations in Colorectal Cancer.
@nl
type
label
The First-in-class Anti-EGFR A ...... utations in Colorectal Cancer.
@ast
The First-in-class Anti-EGFR A ...... utations in Colorectal Cancer.
@en
The First-in-class Anti-EGFR A ...... utations in Colorectal Cancer.
@nl
prefLabel
The First-in-class Anti-EGFR A ...... utations in Colorectal Cancer.
@ast
The First-in-class Anti-EGFR A ...... utations in Colorectal Cancer.
@en
The First-in-class Anti-EGFR A ...... utations in Colorectal Cancer.
@nl
P2093
P50
P921
P3181
P1476
The First-in-class Anti-EGFR A ...... utations in Colorectal Cancer.
@en
P2093
Alba Dalmases
Alejandro Martinez
Ana Rovira
Beatriz Bellosillo
Christopher Stroh
Clara Montagut
Guillem Argilés
Israel Cañadas
Ivan David Horak
Joan Albanell
P304
P3181
P356
10.1158/1078-0432.CCR-15-2400
P407
P577
2016-07-01T00:00:00Z